ARGENX PRESENTS NEW EFGARTIGIMOD DATA AT EULAR 2025 HIGHLIGHTING POSITIVE PHASE 2 PROOF-OF-CONCEPT RESULTS IN MYOSITIS AND SJOGREN’S DISEASE

Reuters · 6d ago

Please log in to view news